Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Hematology
•
Pediatric Hematology
•
Benign Hematology
•
Hemophilia
In light of the Haven 7 trial results, what considerations should be made regarding the monitoring and management of potential long-term adverse effects of emicizumab in infants?
Related Questions
How would you approach secondary stroke prevention in an adult with Hemoglobin SC disease?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
For mild to moderate hemophilia B, do you routinely screen for inhibitors?
Is there any benefit to using desmopressin over vWF replacement therapy for vWD?
How do you counsel patients with acute intermittent porphyria when it comes to fasting for religious reasons?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
How do you manage hemophilia A carriers with no history of bleeding complications but with mildly low factor VIII activity (6-40%)?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
How do you manage significant asymptomatic indirect hyperbilirubinemia in patients with hemolytic diseases (SCD, HS, etc.)?
